Vestibular Schwannoma News and Research

RSS

Does tinnitus cause hearing loss in normal hearing individuals?

Whether cochlear neural degeneration occurs in normal-hearing individuals with tinnitus.

4 Dec 2023

Study shows effectiveness, safety of stereotactic radiosurgery for NF2-related vestibular schwannomas

Vestibular schwannomas related to neurofibromatosis type 2 (NF2) are difficult to manage and are sometimes treated with a noninvasive option, stereotactic radiosurgery.

18 Apr 2023

Research: Patient's race may influence recommendations for surgical resection of brain tumors

Published in The Lancet, University of Minnesota Medical School researchers found a patient's race may influence recommendations for surgical removal of brain tumors.

15 Dec 2022

New study to investigate focused ultrasound's role in addressing neurofibromatosis type 2

The Focused Ultrasound Foundation and the Children's Tumor Foundation (CTF) have established a partnership to advance innovative, noninvasive treatments in pediatrics.

21 Jul 2022

‘Hypervitaminosis D’ is on the rise and linked to serious health issues

'Overdosing' on vitamin D supplements is both possible and harmful, warn doctors in the journal BMJ Case Reports after they treated a man who needed hospital admission for his excessive vitamin D intake.

6 Jul 2022

Antihypertension drug may benefit patients with neurofibromatosis type 2

New research led by investigators at Massachusetts General Hospital and Massachusetts Eye and Ear indicates that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2 (NF2), a hereditary condition associated with vestibular schwannomas, or noncancerous tumors along the nerves in the brain that are involved with hearing and balance.

15 Jul 2021

Sodium fluorescein may improve the safety and outcomes of vestibular schwannoma surgery

Removing a vestibular schwannoma -; a slow-growing, benign tumor that develops in the nerves connecting the inner ear to the brain -; is a delicate procedure. Surgeons must differentiate the tumor from nearby nerves, arteries, and other intracranial structures.

26 Jan 2021

FDA-approved drug for chemical abortion shows promise for treatment of vestibular schwannoma

Massachusetts Eye and Ear researchers have shown that mifepristone, a drug currently FDA-approved for chemical abortion, prevents the growth of vestibular schwannoma cells. This sometimes-lethal intracranial tumor typically causes hearing loss and tinnitus

3 Apr 2018

Surgical partners successfully remove nearly 2,000 cranial base tumors

In one of the nation's longest and most successful surgical partnerships, Loyola Medicine neurosurgeon Douglas Anderson, MD, and otologic surgeon John Leonetti, MD, have worked together to remove nearly 2,000 cranial base tumors during the past 30 years.

19 Apr 2017

Surgeons succeed in removing benign tumour on vestibular nerve that causes deafness

A vestibular schwannoma is a benign tumour consisting of connective tissue and nerve tissue. It is still not known what causes it. 1 - 2 people in every 100,000 develop this type of tumour, which usually presses on the vestibular nerve and at the same time damages the auditory nerve.

27 Feb 2017

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing.

15 Mar 2016

New study reveals why some vestibular schwannomas cause hearing loss

A new study at Massachusetts Eye and Ear showed that in some cases of vestibular schwannoma, a sometimes-lethal tumor often associated with neurofibromatosis 2 (NF2), secretions from the tumor contain toxic molecules that damage the inner ear.

23 Dec 2015

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers from the Eaton-Peabody Laboratories of Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology Program in Speech and Hearing Bioscience and Technology have revealed new understanding of the pathobiology behind a head and neck tumor that may someday lead to new methods of targeted drug therapy.

21 Feb 2015

Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

9 Feb 2015

Northwestern Medicine neurosurgeons use new adaptive hybrid surgery technology to treat brain tumor

It started with numbness on the left side of his face. A few months later, Steve Mores couldn't feel his tongue or chew on the left side of his mouth. TV commercials featuring food or even being in a grocery store made him nauseous. A long time drummer in a popular band, Mores lost 30 pounds and had to find a replacement.

3 Dec 2014

Researchers explore gene expression in normal vestibular nerves, vestibular schwannomas

Researchers from the University of Toronto, directed by Drs. Gelareh Zadeh and Boris Krischek, investigated gene expression in normal vestibular nerves and vestibular schwannomas (VSs).

24 Sep 2014

Aspirin intake correlates with halted growth of lethal intracranial tumor

Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

24 Jan 2014